Context Therapeutics (Context Therapeutics) Total Assets : $11.05 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Total Assets?

Context Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $11.05 Mil.

During the past 12 months, Context Therapeutics's average Total Assets Growth Rate was -56.20% per year. During the past 3 years, the average Total Assets Growth Rate was 109.30% per year.

During the past 5 years, Context Therapeutics's highest 3-Year average Total Assets Growth Rate was 274.50%. The lowest was 109.30%. And the median was 191.90%.

Total Assets is connected with ROA %. Context Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -108.22%. Total Assets is also linked to Revenue through Asset Turnover. Context Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Context Therapeutics Total Assets Historical Data

The historical data trend for Context Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Total Assets Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

0.27

0.47

51.31

37.97

16.06

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial													31.97	27.76	22.99	16.06	11.05

Context Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Context Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	11.871	+	4.192
	=	16.06

Context Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	8.443	+	2.608
	=	11.05

Context Therapeutics (NAS:CNTX) Total Assets Explanation

Total Assets is connected with ROA %.

Context Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-14.672	/	( (16.063	+	11.052)	/ 2 )
	=	-14.672	/	13.5575
	=	-108.22 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Context Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (16.063	+	11.052)	/ 2 )
=	0	/	13.5575
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Context Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104